AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03535688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 200 mg twice daily
Study NCT01379625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin
Description: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
Study NCT01379625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
Study NCT04748263 — intervention group
Intervention type: OTHER
Intervention: No intervention. Only survey and normal use of eye-tracking
Description: The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE.
Study NCT03535688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study NCT01178021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2
Study NCT01178021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine/Primaquine
Description: Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
Study NCT05247411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life.
Study NCT04179903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical Activity program is performed in a group in a gym and at home
Study NCT04475328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AngongNiuhuang pill
Description: This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
Study NCT04475328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AngongNiuhuang pill
Description: This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
Study NCT04475328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke
Study NCT04475328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke
Study NCT02748343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: allograft bone
Description: Use of the allograft bone to treat the bone defect in patients
Study NCT02748343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tissue-engineered bone
Description: Use of the tissue-engineered bone to treat the bone defect in patients
Study NCT04442607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence image processing
Description: Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
Study NCT03139292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway
Description: ProSeal Laryngeal Mask Airway was used as the supraglottic device
Study NCT03139292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmbuAuraGain Laryngeal Mask Airway
Description: AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
Study NCT00743236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: warm ischemia procedure
Description: Warm ischemia followed by partial nephrectomy
Study NCT04590248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Study NCT03077867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus floor augmentation with bone graft
Description: sinus floor augmentation with lateral approach with bone graft
Study NCT03077867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor augmentation with bone graft
Description: sinus floor augmentation with lateral approach with bone graft
Study NCT02617251 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03469076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YUN ACN Cream
Description: YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
Study NCT04435340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Selective Sonography of the ventral abdominal hernia level
Description: The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
Study NCT03152292 — intervention group
Intervention type: OTHER
Intervention: Real-world, non-interventional
Description: N/A - non-interventional
Study NCT00744289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Incentive condition
Description: Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
Study NCT03822910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pattern Separation Paradigm
Description: Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
Study NCT04601454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation System
Description: Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
Study NCT03603366 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
Study NCT02634476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol approach/avoidance task
Description: The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
Study NCT02634476 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham approach/avoidance task
Description: The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
Study NCT02605044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (AB1010)
Study NCT02605044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Study NCT02605044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Study NCT03532607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patients will listen to soothing music for 30 minutes before their standard of care botox injection
Study NCT00178503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate-extended release
Description: Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
Study NCT00178503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate-immediate release
Description: Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
Study NCT00178503 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
Study NCT03584529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 3
Description: Non-Vitamin D3 Drops group Patients in this group would take nothing.
Study NCT01095094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Given orally
Study NCT01095094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir
Description: Given orally
Study NCT00280111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 116E AGMK
Description: Single dose of 116E 10\^5 FFu
Study NCT00280111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I321
Description: Single dose of I321 10\^5 FFu
Study NCT00280111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
Study NCT01027390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training exercise
Description: physical exercise training at the work site during work time
Study NCT03725254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphadenectomy
Description: The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
Study NCT03725254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
Study NCT01518738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breath attention training
Description: 4 week training
Study NCT01518738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: working memory attention training
Description: 4 week training
Study NCT05905614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336 Tablets
Description: Open-label SPH4336 Tablets ：Administered by oral
Study NCT03841981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory blood pressure monitoring
Description: A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).
Study NCT03841981 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous biopsy
Description: Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
Study NCT01886560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
Study NCT03822910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sequential Associative Mismatch Paradigm
Description: used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
Study NCT03841981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic function studies
Description: Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
Study NCT03841981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral smear and feces specimen
Description: Microbiome studies.
Study NCT03822910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Encoding Plasticity Paradigm
Description: Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
Study NCT03777514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: treatment of iron deficiency anemia with IV iron.
Study NCT03777514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: treatment of iron deficiency anemia with oral iron
Study NCT03777514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral vitamin C
Description: Oral vitamin C to be used as a placebo for participants receiving IV iron
Study NCT03777514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous normal saline
Description: Intravenous normal saline will be used as placebo for participants receiving oral iron
Study NCT02176486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study NCT02176486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib placebo-matching capsules.
Study NCT05066685 — intervention group
Intervention type: OTHER
Intervention: All participants
Description: All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
Study NCT02351102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Study NCT02351102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01492010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: 25 g whey protein
Study NCT01492010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplemented with leucine
Description: 6.25 g whey protein supplemented with free form leucine
Study NCT01492010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplemented with essential amino acids
Description: 6.25 g whey protein supplemented with essential amino acids devoid of leucine
Study NCT03505268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
Study NCT04239209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indirect - other patients
Description: Video depicting an indirect response focusing on a comparison to other patients.
Study NCT04239209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indirect - physiology
Description: Video of an indirect response focusing on the physiology of the patient.
Study NCT04239209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Redirection
Description: Video of a redirection towards discussing the patient's values and possible future decisions.
Study NCT04239209 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Direct communication
Description: Video of a direct response.
Study NCT04814979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Description: Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities \<100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.
Study NCT04814979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days.
Study NCT04814979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days.
Study NCT02846519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
Study NCT02846519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 2 capsules (300 mg each) of rifampin.
Study NCT00336102 — intervention group
Intervention type: OTHER
Intervention: physiologic testing
Description: Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
Study NCT00336102 — intervention group
Intervention type: PROCEDURE
Intervention: fatigue assessment and management
Description: Fatigue Symptoms Inventory (FSI) survey
Study NCT00336102 — intervention group
Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
Study NCT03494283 — intervention group
Intervention type: BEHAVIORAL
Intervention: Practice Behaviour
Description: Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
Study NCT00815646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
Study NCT03146286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated fat
Description: Palm stearin
Study NCT03146286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water